Tourmaline shares fall on Phase 2 data; Schrödinger cuts staff

Tourmaline drug cuts inflammation tied to heart disease

Tourmaline Bio said Tuesday that its experimental antibody treatment demonstrated deep reductions in a measure of inflammation often tied to heart disease, although a high placebo response in the mid-stage study may muddy interpretation of the outcome.   In the Phase 2 study called TRANQUILITY, the highest dose of the Tourmaline drug lowered by 86% the levels of high-sensitivity C-reactive protein (hs-CRP), a measure of inflammation, through 90 …

Tourmaline shares fall on Phase 2 data; Schrödinger cuts staff

Tourmaline Bio disclosed results for a potential rival to a Novo Nordisk drug. Elsewhere, data emerged for a psychedelic and CRISPR Therapeutics expanded its toolkit.

Tourmaline Bio's heart drug cuts inflammation as it seeks to compete with Novo, CSL's assets

Tourmaline Bio's experimental drug for atherosclerotic heart disease reduced markers of inflammation in the blood in a mid-stage study. The company must now show the drug cuts key events such as heart attack, stroke and ...